Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City

García-García, Ma. de Lourdes; Valdespino-Gómez, José Luis; Lazcano‐Ponce, Eduardo; Jiménez-Corona, Aída; Higuera-Iglesias, Anjarath Lorena; Cruz-Hervert, Luis Pablo; Cano-Arellano, Bulmaro; Garcia-Anaya, Antonio; Ferreira-Guerrero, Elizabeth; Baéz‐Saldaña, Renata; Ferreyra-Reyes, Leticia; Ponce-de-León-Rosales, Samuel; Alpuche-Aranda, Celia; Rodríguez-López, Mario Henry; Pérez‐Padilla, Rogelio; Hernández-Ávila, Mauricio

doi:10.1136/bmj.b3928

Cited by 140 publications

(106 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…infection with influenza A(H1N1)pdm09 is uncertain, and a range of estimates have been made, which range from indicating protection, [10][11][12][13] to no effect, [14][15][16][17][18][19][20][21][22][23] to increased susceptibility. [24][25][26] A recent meta-analysis found that prior receipt of seasonal influenza vaccination may have been associated with moderate protection against influenza A(H1N1)pdm09.…”

Section: Resultsmentioning

confidence: 99%

Pandemic influenza A(H1N1)pdm09: risk of infection in primary healthcare workers

Hudson¹,

Toop²,

Mangin³

et al. 2013

Br J Gen Pract

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Pandemic influenza A(H1N1)pdm09: risk of infection in primary healthcare workers

Hudson¹,

Toop²,

Mangin³

et al. 2013

Br J Gen Pract

View full text Add to dashboard Cite

show abstract

“…We designed this study in mice to examine the contribution of prior exposure to seasonal influenza vaccination or infection to the immune response to and efficacy of a 2009 p-H1N1 vaccine (6,(12)(13)(14)(15)(16). We focused on p-LAIV rather than the inactivated pandemic vaccine because the breadth of the immune responses induced by LAIV in naïve mice is greater than inactivated vaccine (Figs.…”

Section: Discussionmentioning

confidence: 99%

“…In two studies conducted in the United States and Australia, prior seasonal influenza vaccination did not have a significant effect on the incidence of p-H1N1 infection (6,12). In contrast, in a small retrospective case-control study in Mexico, more severe clinical outcomes were noted among individuals infected with the p-H1N1 virus who had not been previously vaccinated with the 2008-2009 seasonal influenza vaccine (13). Another retrospective analysis in Mexico also noted a lowered risk of p-H1N1 infection among individuals who had been vaccinated with seasonal influenza vaccine (14).…”

mentioning

confidence: 96%

Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine

Chen

Lau

Lamirande

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The robust immune response to a single dose of pandemic 2009 H1N1 vaccine suggests that a large segment of the population has been previously primed. We evaluated the effect of seasonal (s) H1N1 infection, s-trivalent inactivated vaccine (s-TIV), and trivalent s-live attenuated influenza vaccine (s-LAIV) before immunization with a pandemic live attenuated influenza vaccine (p-LAIV) in mice. We compared serum and mucosal antibody and pulmonary CD8 and CD4 responses and the virologic response to challenge with a wild-type 2009 pandemic H1N1 (p-H1N1) virus. Two doses of p-LAIV induced cellular immune and robust ELISA and neutralizing antibody responses that were associated with complete protection from p-H1N1 challenge. A single dose of p-LAIV induced a cellular response and ELISA but not a neutralizing antibody response, and incomplete protection from p-H1N1 virus challenge. Primary infection with s-H1N1 influenza virus followed by a dose of p-LAIV resulted in cross-reactive ELISA antibodies and a robust cellular immune response that was also associated with complete protection from p-H1N1 virus challenge. A lower-magnitude but similar response associated with partial protection was seen in mice that received a dose of s-LAIV followed by p-LAIV. Mice that received a dose of s-TIV followed by p-LAIV did not show any evidence of priming. In summary, prior infection with a seasonal influenza virus or s-LAIV primed mice for a robust response to a single dose of p-LAIV that was associated with protection equivalent to two doses of the matched pandemic vaccine.

show abstract

“…These findings suggest that vaccination with seasonal influenza vaccines might still be of benefit in this pandemic, at least in some cases, in terms of the induction of cross-reactive CTLs. Indeed, recent epidemiological studies also showed that seasonal trivalent inactivated influenza vaccine (TIV) could provide some protection (16,19), although the seasonal influenza vaccine does not stimulate protective antibody responses to pdmH1N1.…”

Section: Cross-response Of Bulk Ctls Against Pdmh1n1 In Healthy Indivmentioning

confidence: 99%

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

Mao

Zheng

et al. 2010

J Virol

138

127

View full text Add to dashboard Cite

While few children and young adults have cross-protective antibodies to the pandemic H1N1 2009 (pdmH1N1) virus, the illness remains mild. The biological reasons for these epidemiological observations are unclear. In this study, we demonstrate that the bulk memory cytotoxic T lymphocytes (CTLs) established by seasonal influenza viruses from healthy individuals who have not been exposed to pdmH1N1 can directly lyse pdmH1N1-infected target cells and produce gamma interferon (IFN-␥) and tumor necrosis factor alpha (TNF-␣). Using influenza A virus matrix protein 1 (M1 58-66 ) epitope-specific CTLs isolated from healthy HLA-A2 ؉ individuals, we further found that M1 58-66 epitope-specific CTLs efficiently killed both M1 58-66 peptide-pulsed and pdmH1N1-infected target cells ex vivo. These M1 58-66 -specific CTLs showed an effector memory phenotype and expressed CXCR3 and CCR5 chemokine receptors. Of 94 influenza A virus CD8 T-cell epitopes obtained from the Immune Epitope Database (IEDB), 17 epitopes are conserved in pdmH1N1, and more than half of these conserved epitopes are derived from M1 protein. In addition, 65% (11/17) of these epitopes were 100% conserved in seasonal influenza vaccine H1N1 strains during the last 20 years. Importantly, seasonal influenza vaccination could expand the functional M1 58-66 epitope-specific CTLs in 20% (4/20) of HLA-A2 ؉ individuals. Our results indicated that memory CTLs established by seasonal influenza A viruses or vaccines had cross-reactivity against pdmH1N1. These might explain, at least in part, the unexpected mild pdmH1N1 illness in the community and also might provide some valuable insights for the future design of broadly protective vaccines to prevent influenza, especially pandemic influenza.

show abstract

Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City

Abstract: Objective To evaluate the association of 2008-9

Cited by 140 publications

References 18 publications

Pandemic influenza A(H1N1)pdm09: risk of infection in primary healthcare workers

Pandemic influenza A(H1N1)pdm09: risk of infection in primary healthcare workers

Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

Contact Info

Product

Resources

About